MedTrace Logo

Study to Evaluate the Efficacy and Safety of Staccato Apomorphine (AZ-009) in Patients With Parkinson's Disease Experiencing OFF Episodes

NCT05979415 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2025-10-21

No results posted yet for this study

Summary

This study will be conducted with In-clinic visits and treatment at home for each patient with established Parkinson's disease (PD) experiencing daily OFF episodes.

Conditions

  • Parkinson Disease

Interventions

DRUG

Apomorphine Cartridge

Staccato Cartridge

Sponsors & Collaborators

  • Peachtree BioResearch Solutions Inc.

    collaborator UNKNOWN

  • DSG, Inc

    collaborator UNKNOWN

  • ISS, Inc.

    collaborator INDUSTRY

  • Alexza Pharmaceuticals, Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
30 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-09-27
Primary Completion
2024-02-28
Completion
2024-02-28
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05979415 on ClinicalTrials.gov